A part of Watch Media

MedWatchTuesday3 October 2023

  • Latest
  • Search
  • Log in
  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
  • Search
  • Log in
MedWatchTuesday3 October 2023
  • Search
  • Log in
  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
Pharma & biotech

FDA advisory committee vote in favor of Lundbeck and Otsuka's Alzheimer's agitation drug Rexulti

Advisory committee at the FDA have voted in favor of Lundbeck and Otsuka Pharmaceuticals’ Brexpiprazole for the treatment of Alzheimer’s agitation.
Photo: Lundbeck / Pr
Photo: Lundbeck / Pr
by marketwire & medwatch

An advisory committee at the Food and Drug Administration (FDA), on Friday voted in favor of approving Lundbeck and Otsuka Pharmaceuticals’ Brexpiprazole for the treatment of agitation in Alzheimer’s patients.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must contain at least 6 characters
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Related articles:

  • The FDA's panels will vote on whether Lundbeck and Otsuka's data sufficiently shows there areAlzheimer's patients who stand to benefit from treating agitation with brexipiprazole | Photo: Jens Dresling/Politiken/Ritzau Scanpix

    Lundbeck and Otsuka await important exam results on Friday for potential Alzheimer's drug

    For subscribers

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Photo: Tom Little
Pharma & biotech

FDA approves Novo Nordisk drug to treat rare condition

The marketing authorization applies to children and adolescents aged 9 years and older, as well as adults with ”relatively” preserved kidney functions.
  • FDA to review Novo Nordisk drug for rare metabolic disease
  • Huge acquisition scores Novo Nordisk an FDA-ready treatment

For subscribers



Fujifilm Diosynth Biotechnologies' factory in Hillerød, Denmark. | Foto: Liselotte Plenov / Fotorummet / Pr
Pharma & biotech

Fujifilm expands management with former Leo executive

For subscribers



Foto: Andrew Kelly/Reuters/Ritzau Scanpix
Pharma & biotech

Low share price may knock Galecto off the stock exchange

For subscribers


Foto: Mike Segar/Reuters/Ritzau Scanpix
Pharma & biotech

Snack maker keeps an eye on Novo Nordisk's obesity drug


Foto: Yuriko Nakao/Reuters/Ritzau Scanpix
Medtech

Olympus appoints new chief medical officer

For subscribers


Foto: Alexander Heinl/AP/Ritzau Scanpix
Pharma & biotech

Novo Nordisk's semaglutide to be studied for positive effect on alcoholics

For subscribers


  • Vaccine breakthrough behind mRNA shots wins Nobel Prize

    The two scientists will share the 11 million-krona ( USD 1 million) award, the Nobel Assembly at the Karolinska Institutet in Stockholm said in a statement Monday.

    For subscribers


  • Foto: Ws Audiology / Pr

    WS Audiology hires new chief technology officer from car manufacturer

    He succeeds chief research & development officer Stefan Menzl, who is stepping down after six years.

    For subscribers


  • Foto: Tom Little

    Novo Nordisk files lawsuit against US authorities ahead of price negotiation

    The litigation is the latest in a long line of industry lawsuits related to price negotiations.

    For subscribers


  • Foto: Mike Segar

    FDA rejects atopic dermatitis drug lebrikizumab

    Eli Lilly had expected a launch this year.

    For subscribers


  • The FDA has updated the package label of Novo Nordisk's diabetes drug, Ozempic, with a warning about intestinal blockage disorder as a possible side effect. | Foto: Tom Little/Reuters/Ritzau Scanpix

    FDA updates Novo Nordisk's Ozempic drug label with side effect alert

    The diabetes drug might cause a potentially fatal intestinal blockage, the authorities warn.

    For subscribers


  • Foto: Anushree Fadnavis/Reuters/Ritzau Scanpix

    Country Manager: Indians will have to wait for Wegovy until 2026

    Up to 40% of the female population aged 30-49 in India is overweight.

    For subscribers


Further reading

Photo: Tom Little
Pharma & biotech

FDA approves Novo Nordisk drug to treat rare condition

The marketing authorization applies to children and adolescents aged 9 years and older, as well as adults with ”relatively” preserved kidney functions.

For subscribers



Fujifilm Diosynth Biotechnologies' factory in Hillerød, Denmark. | Foto: Liselotte Plenov / Fotorummet / Pr
Pharma & biotech

Fujifilm expands management with former Leo executive

The contract manufacturer has hired a chief people officer with immediate effect.

For subscribers



Foto: Mike Segar/Reuters/Ritzau Scanpix
Pharma & biotech

Snack maker keeps an eye on Novo Nordisk's obesity drug

”As with anything that could potentially impact our business, we’re looking at it,” says the former Kellogg’s CEO.

Foto: Alexander Heinl/AP/Ritzau Scanpix
Pharma & biotech

Novo Nordisk's semaglutide to be studied for positive effect on alcoholics

Previous studies have shown that alcohol cravings disappeared when people were treated with GLP-1 agonist exanatide.

For subscribers



Genmab CEO Jan van de Winkel and director general of The Confederation of Danish Industry, Lars Sandahl Sørensen. | Foto: Genmab / PR
Pharma & biotech

Genmab has officially opened its new headquarters

The CEO describes the new premises as a symbol of the company’s commitment to advancing science and innovation.

For subscribers



Lundbeck og Otsuka vil nu dykke længere ned i resultaterne, inden der foretages en endelig evaluerering af de to forsøg. | Photo: Lundbeck / Pr
Pharma & biotech

Lundbeck and Otsuka get mixed PhIII results in PTSD

Lundbeck and Otsuka have announced mixed results from their Phase III studies of brexpiprazole in combination with sertraline for the treatment of PTSD in adults.

For subscribers


Jobs

  • Senior Legal Councel

  • Audit & Supplier Manager

  • Global Medical Manager

  • Clinical Trial Manager

  • Scientist - Bioanalysis, Biologics

  • Senior CMC Specialist, Upstream Processing, Genmab

  • Clinical Supply Manager

  • Director, Head of Antibody Technology

  • Qualified Person to AJ Vaccines

  • Supply Value Stream (SVS) Project Manager

  • Project Director, HR & ESG

  • Senior Analytical Scientists

  • VP of Software Development, Perfusion Tech

  • QA/RA Manager

  • Senior QA Specialists (GMP or GCP)

See all jobs

Latest news

  • Novo Nordisk's semaglutide to be studied for positive effect on alcoholics –
  • Olympus appoints new chief medical officer –
  • Low share price may knock Galecto off the stock exchange –
  • Fujifilm expands management with former Leo executive –
  • Snack maker keeps an eye on Novo Nordisk's obesity drug –
  • FDA approves Novo Nordisk drug to treat rare condition –
  • FDA updates Novo Nordisk's Ozempic drug label with side effect alert –
  • FDA rejects atopic dermatitis drug lebrikizumab –
  • FDA to support new orphan drugs through pilot program –
  • Vaccine breakthrough behind mRNA shots wins Nobel Prize –
See all

Jobs

  • Senior Legal Councel

  • Audit & Supplier Manager

  • Global Medical Manager

  • Clinical Trial Manager

  • Scientist - Bioanalysis, Biologics

  • Senior CMC Specialist, Upstream Processing, Genmab

  • Clinical Supply Manager

  • Director, Head of Antibody Technology

  • Qualified Person to AJ Vaccines

  • Supply Value Stream (SVS) Project Manager

  • Project Director, HR & ESG

  • Senior Analytical Scientists

  • VP of Software Development, Perfusion Tech

  • QA/RA Manager

  • Senior QA Specialists (GMP or GCP)

See all jobs

Colophon

MedWatch
Search

Sections

  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
  • Sitemap
  • RSS feeds

Editor

Mikkel Aabenhus Hemmingsen

mah@medwatch.dk

Tel.: +45 3330 8387

  • About MedWatch

Editor-in-chief

Anders Heering

Publisher

JP/Politiken Media Group Ltd

Banner Advertising

annoncering@infowatch.dk

Tel.: +45 7077 7441

Advertising

Job Advertising

job@infowatch.dk

Tel.: +45 7077 7441

Jobs

Subscription

Try MedWatch or get an offer for a subscription meeting the exact needs of you or your company.

medwatch@infowatch.dk

Tel.: +45 7077 7441

Learn more about subscriptions here

Address

MedWatch

Rådhuspladsen 37

1785 Copenhagen K, Denmark

Tel.: +45 3330 8370

Guidelines

  • Privacy Policy

Copyright © MedWatch — All rights reserved